197 related articles for article (PubMed ID: 34050985)
1. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Mohan M; Szabo A; Yarlagadda N; Gundarlapalli S; Thanendrarajan S; Kendrick S; Schinke C; Alapat D; Sawyer J; Tian E; Tricot G; van Rhee F; Zangari M
Am J Hematol; 2021 Sep; 96(9):E341-E344. PubMed ID: 34050985
[No Abstract] [Full Text] [Related]
2. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
3. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B; Yuan C; Dogan A; Stetler-Stevenson M; Marti GE
Am J Hematol; 2014 Dec; 89(12):1159-60. PubMed ID: 25132630
[No Abstract] [Full Text] [Related]
4. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
[TBL] [Abstract][Full Text] [Related]
5. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
Came N; Nguyen V; Westerman D; Harrison S
Br J Haematol; 2016 Jun; 173(6):947-9. PubMed ID: 26456706
[No Abstract] [Full Text] [Related]
6. Minimal residual disease in multiple myeloma: use of magnetic resonance imaging.
Hillengass J; Merz M; Delorme S
Semin Hematol; 2018 Jan; 55(1):19-21. PubMed ID: 29759148
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma.
Pugh TJ
Semin Hematol; 2018 Jan; 55(1):38-40. PubMed ID: 29759151
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
Flanders A; Stetler-Stevenson M; Landgren O
Blood; 2013 Aug; 122(6):1088-9. PubMed ID: 23929839
[No Abstract] [Full Text] [Related]
9. Some limitations in the detection of residual aneuploid cells with dna quantification on immunophenotyped cells by flow cytometry.
Nowak R; Oelschlägel U; Heider T; Naumann R; Ehninger G
Br J Haematol; 2000 Sep; 110(3):751-3. PubMed ID: 10997996
[No Abstract] [Full Text] [Related]
10. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
Avet-Loiseau H
Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
Thoren KL
Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
13. [Multiple myeloma].
Krome S
Dtsch Med Wochenschr; 2012 Mar; 137 Suppl 1():S14-7. PubMed ID: 22438117
[No Abstract] [Full Text] [Related]
14. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
15. Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care.
Catamero D
Clin J Oncol Nurs; 2018 Jun; 22(3):263-265. PubMed ID: 29781462
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma: disease response assessment.
Zamagni E; Tacchetti P; Terragna C; Cavo M
Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
[TBL] [Abstract][Full Text] [Related]
19. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
[TBL] [Abstract][Full Text] [Related]
20. MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool.
Landgren O
Semin Hematol; 2018 Jan; 55(1):1-3. PubMed ID: 29759146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
